Erich Bluhmki
Boehringer Ingelheim (Germany)
2 papers in the Anchorcite directory, published between 2008 and 2015, cited 19,434 times in total.
ORCID profileResearch topics
- Diabetes, Cardiovascular Risks, and Lipoproteins · 1 paper
- Diabetes Treatment and Management · 1 paper
- Heart Failure Treatment and Management · 1 paper
- Intracerebral and Subarachnoid Hemorrhage Research · 1 paper
- Acute Ischemic Stroke Management · 1 paper
- Acute Myocardial Infarction Research · 1 paper
Frequent co-authors
- Bernard Zinman · 1 paper
- Christoph Wanner · 1 paper
- John M. Lachin · 1 paper
- DAVID H. FITCHETT · 1 paper
- Stefan Hantel · 1 paper
- Michaela Mattheus · 1 paper
- Theresa Devins · 1 paper
- Odd Erik Johansen · 1 paper
Papers
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine · 2015 · 12,596 citations
BACKGROUND: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. METHODS: We randomly assigned patients to…
- Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic StrokeNew England Journal of Medicine · 2008 · 6,838 citations
BACKGROUND: Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after the onset of symptoms have not been established. We tested the efficacy and safety…
Metadata from OpenAlex (CC0).